Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N J Curtin

Showing results (11-20 of 48) with videos related to

Pageof 5
Sort By:
Cancer Research|May 1, 1991
Mechanism of cell death following thymidylate synthase inhibition: 2'-deoxyuridine-5'-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamoleN J Curtin, A L Harris, G W Aherne
Oncogene|June 30, 2007
Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancerA C Rigas, C N Robson, N J Curtin
Biochemical Pharmacology|October 1, 1989
Modulation of dipyridamole action by alpha 1 acid glycoprotein. Reduced potentiation of quinazoline antifolate (CB3717) cytotoxicity by dipyridamoleN J Curtin, D R Newell, A L Harris
British Journal of Cancer|January 1, 1997
Selective potentiation of lometrexol growth inhibition by dipyridamole through cell-specific inhibition of hypoxanthine salvageR N Turner, G W Aherne, N J Curtin
The British Journal of Radiology|October 10, 2008
Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancerS Kyle, H D Thomas, J Mitchell, et al.
British Journal of Cancer|March 25, 2000
Dipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transportP G Smith, E Marshman, D R Newell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2001
The impact of p53 status on cellular sensitivity to antifolate drugsX Lu, J Errington, N J Curtin, et al.
British Journal of Cancer|January 5, 2001
Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitroK J Bowman, D R Newell, A H Calvert, et al.
British Journal of Cancer|March 1, 1986
Inhibition of the growth of human hepatocellular carcinoma in vitro and in athymic mice by a quinazoline inhibitor of thymidylate synthase, CB3717N J Curtin, A L Harris, O F James, et al.
Transfusion Medicine (Oxford, England)|June 15, 2007
Delayed haemolytic transfusion reaction due to anti-Jkb in a patient with non-Hodgkin's lymphoma-transient nature of anti-Jkb and the importance of early serological diagnosisS S Hussain, A M Ebbs, N J Curtin, et al.
Pageof 5

Showing results (11-20 of 48) with videos related to

Sort By:
Pageof 5
Cancer Research|May 1, 1991
Mechanism of cell death following thymidylate synthase inhibition: 2'-deoxyuridine-5'-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamoleN J Curtin, A L Harris, G W Aherne
Oncogene|June 30, 2007
Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancerA C Rigas, C N Robson, N J Curtin
Biochemical Pharmacology|October 1, 1989
Modulation of dipyridamole action by alpha 1 acid glycoprotein. Reduced potentiation of quinazoline antifolate (CB3717) cytotoxicity by dipyridamoleN J Curtin, D R Newell, A L Harris
British Journal of Cancer|January 1, 1997
Selective potentiation of lometrexol growth inhibition by dipyridamole through cell-specific inhibition of hypoxanthine salvageR N Turner, G W Aherne, N J Curtin
The British Journal of Radiology|October 10, 2008
Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancerS Kyle, H D Thomas, J Mitchell, et al.
British Journal of Cancer|March 25, 2000
Dipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transportP G Smith, E Marshman, D R Newell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2001
The impact of p53 status on cellular sensitivity to antifolate drugsX Lu, J Errington, N J Curtin, et al.
British Journal of Cancer|January 5, 2001
Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitroK J Bowman, D R Newell, A H Calvert, et al.
British Journal of Cancer|March 1, 1986
Inhibition of the growth of human hepatocellular carcinoma in vitro and in athymic mice by a quinazoline inhibitor of thymidylate synthase, CB3717N J Curtin, A L Harris, O F James, et al.
Transfusion Medicine (Oxford, England)|June 15, 2007
Delayed haemolytic transfusion reaction due to anti-Jkb in a patient with non-Hodgkin's lymphoma-transient nature of anti-Jkb and the importance of early serological diagnosisS S Hussain, A M Ebbs, N J Curtin, et al.
Pageof 5